Investor Relations

Current Press Releases

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

| Source: Arch Biopartners


TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase II study of Metablok (LSALT Peptide), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19. The Company expects to announce results in July 2021.

A total of 65 patients were randomized into the double-blind, placebo-controlled trial and 61 of these patients received at least one treatment dose.

“We would like to thank all of the patients and their families, as well as our clinical site teams in Canada, Turkey and the USA, for helping us ...
Full Release

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

  • Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation
  • Novel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists that prevent leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
  • Cilastatin and Arch drug Metablok are the only known DPEP-1 antagonists that have successfully completed phase I trials
  • New license creates opportunity for a new Phase II trial for Metablok and cilastatin targeting acute kidney injury, which is currently an unmet billion dollar market
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain (“Telara”) to clinically develop and market cilastatin, a small-molecule drug candidate for the treatment and prevention of acute kidney injury (“AKI”). With this license, Arch secures the ...
Full Release

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional patients into the Phase II trial of its lead drug LSALT peptide (Metablok), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

...
Full Release
Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Please enable the javascript to submit this form

Press Release Archives